Start here if you're new
what it is
Corbus is a tiny biotech trying to turn three experimental drugs into cancer and obesity treatments.
how it gets paid
Last year Corbus Pharma made n/a in revenue. collaboration and license revenue was the main engine at $1M, or 100% of sales.
what just happened
Corbus posted just $3M in latest-quarter revenue while EPS fell to -$4.73.
At a glance
C++ balance sheet — some cracks in the foundation
45/100 earnings predictability — expect surprises
-$3.68 fy2024 eps est
$1M fy2021 rev est
1.4 beta
xvary composite: 34/100 — weak
What they do
Corbus is a tiny biotech trying to turn three experimental drugs into cancer and obesity treatments.
The edge here is focus. Corbus has 28 employees and three lead programs, which means your bet is concentrated on a few shots rather than spread across a giant bureaucracy. ADC (antibody-drug conjugate) → a guided cancer drug payload → so what: if CRB-701 works, one asset can matter more than the company’s entire $167M market cap.
How they make money
n/a
annual revenue
collaboration and license revenue
$1M
crb-701 program revenue
$0M
crb-601 program revenue
$0M
crb-913 program revenue
$0M
The products that matter
oncology drug candidate
CRB-701
Fast Track designation · no product revenue
it carries FDA Fast Track status, which can speed development, but it still sits inside a company with just $1M in revenue. if this asset works, it can change the whole story. if it does not, the story gets much smaller.
lead asset
pre-revenue metabolic pipeline
Obesity Pipeline
data expected summer 2026
management has flagged summer 2026 as a catalyst window. for a company valued at $167M, that timing matters more than any quarterly revenue line because there barely is one.
next catalyst
balance sheet support
Cash Position
$163M on hand
the cash balance is almost the market cap. that gives you time, not proof. in biotech, runway is necessary but never sufficient.
runway
Key numbers
-$3.68
2024 EPS
EPS → profit per share → so what: Corbus lost $3.68 per share in 2024, which tells you this is still a funding story, not an earnings story.
$3M
quarterly revenue
Revenue → money coming in → so what: Corbus finally showed $3M in quarterly revenue, but that is tiny next to biotech development costs.
1.4
beta
Beta → how jumpy a stock is versus the market → so what: Corbus tends to move 40% more than the market.
$0M
long-term debt
Debt → borrowed money → so what: no long-term debt removes one problem, but it does not solve ongoing losses.
Financial health
C++
strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 4 — safer than 20% of stocks
- price stability 5 / 100
- long-term debt $0M (0% of capital)
C++ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for CRBP right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Corbus posted just $3M in latest-quarter revenue while EPS fell to -$4.73.
Revenue grew 132% vs. prior year from a very small base. EPS stayed deeply negative, which is the quiet part for a clinical-stage biotech with a $167M market cap.
$3M
revenue
-$4.73
eps
+132%
revenue growth
the number that mattered
$3M matters because it shows some revenue exists, but it is still tiny beside the losses implied by -$4.73 EPS.
source: SEC filing data and quarterly figures provided
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is clinical readout failure for CRB-701 or the obesity pipeline.
med
Clinical data misses
There is no operating business to cushion bad science. With a $167M market cap and no approved products, weak efficacy or safety data would hit the whole thesis at once.
Impact: the company has just $1M in revenue, so almost 100% of the equity story is tied to pipeline credibility.
med
Cash burn outruns catalyst timing
Corbus ended the period with $163M in cash, which sounds comforting until you remember the company is still pre-commercial. If trial timelines slip, runway matters more than optimism.
Impact: the page does not show a full quarterly burn cadence, so you should focus on whether cash is falling faster than milestones are arriving.
med
Dilution from the $300M shelf
The shelf registration gives management flexibility to raise capital. It also creates an overhang because the amount authorized is larger than the current $167M market cap.
Impact: if that shelf is used before a meaningful data win, existing shareholders absorb dilution without getting much de-risking in return.
A forced financing or failed readout would pressure a company with $1M in revenue, $163M in cash, and a $300M dilution tool already on file.
source: institutional data · regulatory filings · risk analysis
Pay attention to
lead catalyst
CRB-701 clinical updates
This is still the lead value driver. The company has Fast Track status here, but what matters next is data that makes the $167M valuation look conservative instead of generous.
calendar
summer 2026 obesity data
Management has already pointed to summer 2026. If that timing slips, you should assume the market will start valuing time-to-data more harshly.
financing risk
cash balance versus shelf usage
$163M in cash is solid relative to a $167M market cap. A move to use the $300M shelf before major data would tell you financing is becoming the main event.
trading signal
volatility around binary headlines
A 52-week range of $5–$21 with a current price of $7.56 is your reminder that biotech re-prices in chunks, not gentle increments.
Analyst rankings
earnings predictability
45 / 100
in human-speak, analysts should not look precise here because the business is not mature enough to be precise.
sell-side target gap
$39 median
That sits roughly 415% above the current price. Either the street is underwriting much better trial odds than the market, or the market is saying dilution and failure risk deserve the discount.
source: institutional data
Institutional activity
institutional ownership data for CRBP is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$8
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive